New and old agents in the management of diabetic nephropathy

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 3, 2016, Pages 232-239

  Lytvyn, Yuliya ^a,b   Bjornstad, Petter ^c,d   Pun, Nicole ^a   Cherney, David Z I ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Advanced glycation end products; Diabetic nephropathy; Incretin based therapy; Neprilysin inhibition; Renin angiotensin aldosterone system; Sodium glucose cotransporter 2 inhibition; Transforming growth factor

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANTIFIBROTIC AGENT; ENKEPHALINASE INHIBITOR; INCRETIN; MEMBRANE METALLOENDOPEPTIDASE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME INHIBITION; FEEDBACK SYSTEM; HUMAN; KIDNEY FIBROSIS; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC; PHYSIOLOGY; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 84958824681     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000214     Document Type: Review

References (67)

1. Lewis G, Maxwell AP. Risk factor control is key in diabetic nephropathy. Practitioner 2014; 258:13-17; 12.
2. Perez-Gomez MV, Sanchez-Nino MD, Sanz AB, et al. Horizon 2020in diabetic kidney disease: the clinical trial pipeline for add-on therapies on top of renin angiotensin system blockade. J Clin Med 2015; 4:1325-1347.
3. Zain M, Awan FR. Renin angiotensin aldosterone system (RAAS): its biology and drug targets for treating diabetic nephropathy. Pakistan J Pharm Sci 2014; 27:1379-1391.
4. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angio-tensin 1-9. Circ Res 2000; 87:E1-E9.
5. Mizuiri S, Ohashi Y. ACE and ACE2 in kidney disease. World J Nephrol 2015; 4:74-82.
6. Marquez E, Riera M, Pascual J, Soler MJ. Renin-angiotensin system within the diabetic podocyte. Am J Physiol Renal Physiol 2015; 308:F1-F10.
7. Soler MJ, Wysocki J, Ye M, et al. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 2007; 72:614-623.
8. Oudit GY, Herzenberg AM, Kassiri Z, et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomer-ulosclerosis. Am J Pathol 2006; 168:1808-1820.
9. Zhong J, Guo D, Chen CB, et al. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 2011; 57:314-322.
10. Nadarajah R, Milagres R, Dilauro M, et al. Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 2012; 82:292-303.
11. Reich HN, Oudit GY, Penninger JM, et al. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 2008; 74:1610-1616.
12. Mizuiri S, Hemmi H, Arita M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 2008; 51:613-623.
13. Anguiano L, Riera M, Pascual J, et al. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. Nephrol Dial Transplant 2015; 30:1176-1185.
14. Liu CX, Hu Q, Wang Y, et al. Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. Mol Med 2011; 17:59-69.
15. Shi Y, Lo CS, Padda R, et al. Angiotensin-(1-7) prevents systemic hyperten-sion, attenuates oxidative stress and tubulointerstitial fibrosis, and normalizes renal angiotensin-converting enzyme 2 and Mas receptor expression in diabetic mice. Clin Sci (Lond) 2015; 128:649-663.
16. Jarajapu YP, Bhatwadekar AD, Caballero S, et al. Activation of the ACE2/angiotensin-(1-7)/Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitors. Diabetes 2013; 62:1258-1269.
17. Hernandez Prada JA, Ferreira AJ, Katovich MJ, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008; 51:1312-1317.
18. Singh K, Sharma K, Singh M, Sharma PL. Possible mechanism of the cardio-renal protective effects of AVE-0991, a nonpeptide Mas-receptor agonist, in diabetic rats. J Renin Angiotensin Aldosterone Syst 2012; 13:334-340.
19. Judge P, Haynes R, Landray MJ, Baigent C. Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant 2015; 30:738-743.
20. Mangiafico S, Costello-Boerrigter LC, Andersen IA, et al. Neutral endopepti-dase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 2013; 34:886-893c.
21. Benigni A, Zoja C, Zatelli C, et al. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney Int 2004; 66:1959-1965.
22. Cao Z, Burrell LM, Tikkanen I, et al. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 2001; 60:715-721.
23. Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108:420-425.
24. Taal MW, Nenov VD, Wong W, et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 2001; 12:2051-2059.
25. Cheng ZJ, Gronholm T, Louhelainen M, et al. Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats. J Hypertens 2005; 23:1757-1770.
26. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993-1004.
27. Packer M, McMurray JJ, Desai AS, et al. Angiotensin recepte or neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015; 131:54-61.
28. Stanton RC. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation 2014; 129:542-544.
29. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 13:28.
30. Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129:587-597.
31. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014; 37:1480-1483.
32. Skrtic M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 2015; 24:96-103.
33. Vallon V, Schroth J, Satriano J, et al. Adenosine A(1) receptors determine glomerular hyperfiltration and the salt paradox in early streptozotocin diabetes mellitus. Nephron Physiol 2009; 111:30-38.
34. Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014; 306:F194-F204.
35. Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells: renoprotection in diabetic nephropathy? PloS One 2013; 8:e54442.
36. Tahara A, Kurosaki E, Yokono M, et al. Effects of sodium-glucose cotran-sporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol 2014; 66:975-987.
37. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diab Endocrinol 2014; 2:369-384.
38. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diab Obes Metab 2013; 15:463-473.
39. Cefalu WT, Leiter LA, Yoon KH, et al. Canagliflozin demonstrates durable glycemic improvements over 104 weeks versus glimepiride in subjects with type 2 diabetes mellitus on metformin. Diabetes 2013; 62 (Supple 1(A912)):65 LB.
40. Lytvyn Y, Skrtic M, Yang GK, et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2015; 308:F77-F83.
41. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012; 8:495-502.
42. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med 2012; 44:375-393.
43. Lytvyn Y, Perkins BA, Cherney DZ. Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes 2015.
44. Kojima N, Williams JM, Takahashi T, et al. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Therap 2013; 345:464-472.
45. Tonneijck L, Smits MM, van Raalte DH, Muskiet MH. Incretin-based drugs and renoprotection-is hyperfiltration key? Kidney Int 2015; 87:660-661.
46. Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005; 48:1168-1172.
47. Ryskjaer J, Deacon CF, Carr RD, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006; 155:485-493.
48. Sun AL, Deng JT, Guan GJ, et al. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab Vasc Dis Res 2012; 9:301-308.
49. Crajoinas RO, Oricchio FT, Pessoa TD, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 2011; 301:F355-F363.
50. Groop PH, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013; 36:3460-3468.
51. Alicic RZ, Tuttle KR. Novel therapies for diabetic kidney disease. Adv Chronic Kidney Dis 2014; 21:121-133.
52. Berg TJ, Bangstad HJ, Torjesen PA, et al. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metab Clin Exp 1997; 46:661-665.
53. Elseweidy MM, Elswefy SE, Younis NN, Zaghloul MS. Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflam-matory cytokines in experimental diabetic nephropathy. Exp Biol Med 2013; 238:881-888.
54. Lewis EJ, Greene T, Spitalewiz S, et al. Pyridorin in type 2 diabetic nephro-pathy. J Am Soc Nephrol 2012; 23:131-136.
55. Dwyer JP, Greco BA, Umanath K, et al. Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study. Nephron 2015; 129:22-28.
56. Tuttle KR, Adler SG, Kretzler M, et al. Baricitinib in diabetic kidney disease: results from a phase 2, multicenter, randomized, double-blind, placebo-controlled study. Paper presented at the American Diabetes Association Meeting; 2015.
57. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, et al. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002; 62:901-913.
58. Chen S, Lee JS, Iglesias-de la Cruz MC, et al. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant 2005; 20:1320-1328.
59. Wahab NA, Schaefer L, Weston BS, et al. Glomerular expression of thrombos-pondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 2005; 48:2650-2660.
60. Benigni A, Zoja C, Corna D, et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003; 14:1816-1824.
61. Petersen M, Thorikay M, Deckers M, et al. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int 2008; 73:705-715.
62. Duffin KL LJ, Greene T, Zaoui P. Renal efficacy and safety of anti-TGF-b1 therapy in patients with diabetic nephropathy [Abstract]. J Am Soc Nephrol 2014. 25(B1).
63. Ramachandra Rao SP, Zhu Y, Ravasi T, et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009; 20:1765-1775.
64. Peng ZZ, Hu GY, Shen H, et al. Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells. Nephrol-ogy (Carlton, Vic) 2009; 14:565-572.
65. Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011; 22:1144-1151.
66. Tang Y, Zhang F, Huang L, et al. The protective mechanism of fluorofenidone in renal interstitial inflammation and fibrosis. Am J Med Sci 2015; 350:195-203.
67. Maahs DM, Caramori L, Cherney DZ, et al. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep 2013; 13:550-559.